Harada M - Search Results

1

Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer.

Fujino M, Dosaka-Akita H, Harada M, Hiroumi H, Kinoshita I, Akie K, Kawakami Y. Fujino M, et al. Among authors: harada m. Cancer. 1995 Dec 15;76(12):2457-63. doi: 10.1002/1097-0142(19951215)76:12<2457::aid-cncr2820761209>3.0.co;2-x. Cancer. 1995. PMID: 8625071

2

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.

Asahina H, Yamazaki K, Kinoshita I, Sukoh N, Harada M, Yokouchi H, Ishida T, Ogura S, Kojima T, Okamoto Y, Fujita Y, Dosaka-Akita H, Isobe H, Nishimura M. Asahina H, et al. Among authors: harada m. Br J Cancer. 2006 Oct 23;95(8):998-1004. doi: 10.1038/sj.bjc.6603393. Br J Cancer. 2006. PMID: 17047648 Free PMC article. Clinical Trial.

3

Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.

Dosaka-Akita H, Hu SX, Fujino M, Harada M, Kinoshita I, Xu HJ, Kuzumaki N, Kawakami Y, Benedict WF. Dosaka-Akita H, et al. Among authors: harada m. Cancer. 1997 Apr 1;79(7):1329-37. Cancer. 1997. PMID: 9083154

4

Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer.

Harada M, Dosaka-Akita H, Miyamoto H, Kuzumaki N, Kawakami Y. Harada M, et al. Cancer. 1992 Jan 1;69(1):72-7. doi: 10.1002/1097-0142(19920101)69:1<72::aid-cncr2820690114>3.0.co;2-a. Cancer. 1992. PMID: 1309311

5

[Clinical significance of oncogene product expression in human lung cancer].

Dosaka-Akita H, Harada M, Miyamoto H, Kawakami Y. Dosaka-Akita H, et al. Among authors: harada m. Nihon Kyobu Shikkan Gakkai Zasshi. 1992 Aug;30(8):1441-7. Nihon Kyobu Shikkan Gakkai Zasshi. 1992. PMID: 1331597 Japanese.

6

Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer.

Miyamoto H, Harada M, Isobe H, Akita HD, Haneda H, Yamaguchi E, Kuzumaki N, Kawakami Y. Miyamoto H, et al. Among authors: harada m. Cancer Res. 1991 Dec 1;51(23 Pt 1):6346-50. Cancer Res. 1991. PMID: 1657384

7

The relationship of clinical classification to ras p21 expression in human non-small cell lung cancer.

Dosaka H, Harada M, Kuzumaki N, Kobayashi H, Miyamoto H, Kawakami Y. Dosaka H, et al. Among authors: harada m. Oncology. 1988;45(5):396-400. doi: 10.1159/000226650. Oncology. 1988. PMID: 2842711

8

[Clinical study of multiple primary cancers including lung cancer].

Ishikuro A, Isobe H, Miyamoto H, Katabami M, Harada M, Kawakami Y, Okayasu K, Inoue K. Ishikuro A, et al. Among authors: harada m. Gan No Rinsho. 1989 Nov;35(14):1636-40. Gan No Rinsho. 1989. PMID: 2593230 Japanese.

9

Immunohistochemical analysis of human lung cancers with anti-ras p21 monoclonal antibodies.

Dosaka H, Harada M, Kuzumaki N, Kobayashi H, Isobe H, Miyamoto H, Kawakami Y. Dosaka H, et al. Among authors: harada m. Int J Biol Markers. 1987 May-Aug;2(2):75-82. doi: 10.1177/172460088700200204. Int J Biol Markers. 1987. PMID: 3330557

10

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.

Sugawara S, Oizumi S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Yoshizawa H, Ito K, Gemma A, Nishitsuji M, Harada M, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Kurihara M, Nukiwa T. Sugawara S, et al. Among authors: harada m, harada t. Ann Oncol. 2015 May;26(5):888-894. doi: 10.1093/annonc/mdv063. Epub 2015 Feb 10. Ann Oncol. 2015. PMID: 25669832 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,864 results

Search Page